Abemaciclib plus letrozole for rare ER-positive ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether abemaciclib with letrozole can slow or shrink certain rare ovarian cancers that have estrogen receptors. It may help people whose cancer has come back and can be measured on scans, with extra required tissue and blood tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and be able to sign consent (or your legal representative can).
- Have a confirmed diagnosis of a rare low-grade ovarian/tube/peritoneal cancer that is estrogen-receptor positive (ER+).
- Your cancer must have come back and have measurable tumors on scans, with specific size cutoffs.
- You must be able to provide tumor tissue (before and during treatment if possible) and blood samples for lab research.
- Your past treatment must fit the trial’s rules: you can’t be “platinum-refractory,” and there are limits on how many hormone (endocrine) treatments you’ve had.
- You need adequate blood counts and organ function (kidney, liver, etc.) and you must not have active serious infections or certain major heart problems.
- You must not be pregnant or breastfeeding, and you must use highly effective birth control during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking two oral medications (letrozole and abemaciclib) after standard chemotherapy can help keep advanced or recurrent endometrial cancer from coming back. It is for people whose cancer is estrogen receptor-positive and has certain favorable genetic features.
This Phase 2 study tests whether adding medicines to standard hormone therapy (letrozole) can control endometrial cancer that has come back, spread, or stopped responding to usual treatments. It also explores whether extra drugs (metformin or gedatolisib) improve results for certain patient groups.
This Phase 2 study tests abemaciclib, a targeted pill treatment, for recurrent ovarian or endometrial cancer that shows specific tumor genetic patterns. It may help slow or control cancer growth in people whose tumor matches the required test results.
This Phase 1 trial studies whether adding abemaciclib to olaparib can treat women with recurrent platinum-resistant ovarian cancer. It aims to find a safe dose and see how well the combination can control the cancer.
This study tests whether letrozole, a hormone-blocking medicine, can help people with newly diagnosed low-grade serous ovarian cancer that has hormone receptor proteins (ER and/or PgR) after surgery. It compares outcomes to see if blocking estrogen can slow the cancer’s return or progression.
This trial tests a combination of two oral targeted drugs (avutometinib and defactinib) plus letrozole (a hormone therapy) in people with low-grade serous ovarian cancer who have not yet had any systemic treatment.
Hear when a new Low Grade Serous Ovarian Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.